Skip to main content
TipRanks
Go Ultimate75% OFF

HLS Therapeutics Inc (74D) Q3 2026 Earnings Report

0 Followers

DE:74D Q3 2026 EPS Results

Actual EPS
-EUR 0.06
Consensus EPS
-EUR 0.06
Beat/Miss
Missed by -EUR 0.00
One Year Ago EPS
-EUR 0.11

DE:74D Q3 2026 Revenue Results

Actual Revenue
EUR 12.60M
Expected Revenue
EUR 13.49M
Beat/Miss
Missed by -EUR 898.82K
YoY Revenue Growth
+6.50%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/12/2026
Time
Before Open
Conference Call
Thursday, November 12, 2026
DE:74D Upcoming Earnings

HLS Therapeutics Inc's next earnings date is estimated for March 18, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

No earnings call audio is available for this earnings event.

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 12, 2026|% Change Since:-11.20%|
Earnings Call Sentiment|Positive

The call was predominantly positive, with strong cardiovascular growth, accelerating NILEMDO adoption, improving cardiovascular profitability, debt reduction, share repurchases and several 2027 growth catalysts. Offsetting issues included declines in Clozaril sales and U.S. year-to-date performance, year-to-date adjusted EBITDA being below the prior year, higher launch-related spending and guidance positioned in the lower half of the 2026 adjusted EBITDA range. Highlights significantly outweighed the lowlights.

Company Guidance

For 2026, the company refined its outlook within previously guided ranges to revenue of $56 million to $60 million and adjusted EBITDA of $18.5 million to $21 million, expecting revenue to be around the midpoint of the range and adjusted EBITDA to be in the lower half of the guidance range; it continues to expect double-digit net sales growth for Vascepa for the full year. The company expects a step-up in growth in both consolidated revenue and adjusted EBITDA in 2027 and then to accelerate further in 2028, with the NILEMDO/NEXLIZET peak sales opportunity in the range of CAD 50 million to CAD 100 million, typically achieved in Canada over 6 to 7 years. It expects pCPA negotiations to begin this month, initial provincial listings for NILEMDO in the first half of 2027, a Health Canada decision on NEXLIZET by year-end and, assuming an approval, launch in the first half of 2027; VERQUVO activities are set to ramp up in the new year with minimal impact on revenue and adjusted EBITDA in 2027, responsibility beginning in Q1 next year, and expected peak revenue of about $5 million to $10 million at peak.

  • Cardiovascular Portfolio GrowthThe cardiovascular portfolio delivered approximately 21% year-over-year net sales growth in Q3 in local currency, and year-to-date growth was 19% in local currency, driven by a 12% increase in Vascepa net sales and the addition of NILEMDO.
  • Q3 Revenue GrowthQ3 revenue was $14.2 million, up 5% year-over-year. Year-to-date revenue was $41.7 million, up 3%.
  • NILEMDO Sales RampNILEMDO generated more than CAD 800,000 of net sales in its second full quarter, up 91% from Q2. Management said the launch was ahead of its initial projections for the year.
  • NILEMDO Patient Starts and Launch MomentumNILEMDO added 1,700 new patients in Q3 and reached 2,900 new patients since launch. New patient starts continued to be over 3x the number started on Vascepa during the same period of its launch, and management said the ramp continued into November without signs of slowing.
  • NILEMDO Prescriber Expansion OpportunityAt the end of Q3, approximately 1 in 5 targeted prescribers had initiated a patient on NILEMDO. Management said there was significant room to expand prescriber breadth and depth as prescribers move from trial to adoption.
  • NILEMDO Private Coverage ExpansionAgreements with private payers covered over 80% of privately insured Canadians, with the vast majority of those patients able to access NILEMDO as a full benefit without restrictions. Management observed a significant step-up in unit demand in September as newly added plans took effect.
  • Expected NILEMDO Public Reimbursement CatalystpCPA negotiations for NILEMDO public reimbursement were expected to begin in November, with initial provincial listings still expected in the first half of 2027. Management described public reimbursement as a major catalyst that could open access to the 2/3 of the market covered by public drug plans.
  • Vascepa Demand GrowthVascepa Q3 net sales grew approximately 8% year-over-year in local currency, while unit demand increased 14%. Year-to-date net sales increased approximately 12% in local currency and units increased 16%; the company continued to expect double-digit net sales growth for the full year.
  • Improving Cardiovascular ProfitabilityAdjusted EBITDA increased to $5 million in Q3 from $4.9 million in Q3 last year and was up sequentially from Q2. Direct brand contribution from the cardiovascular portfolio was $0.7 million in Q3 after breaking even in the first half of the year, indicating that the cardiovascular business had become profitable at the brand level.
  • Improving Operating LeverageManagement said cardiovascular margins were expanding as NILEMDO ramped, with more of each incremental sales dollar flowing through to adjusted EBITDA on the existing commercial infrastructure.
  • VERQUVO Canadian Commercialization AgreementHLS entered into an agreement with Bayer to assume distribution, promotion and medical education support for VERQUVO in Canada starting in the first quarter. VERQUVO already has Health Canada approval and public and private reimbursement in place, while HLS described the deal structure as capital efficient, with payments to Bayer tied to brand commercial success.
  • VERQUVO Strategic OpportunityVERQUVO extends HLS's cardiovascular franchise into heart failure. The company expects to focus initially on heart failure specialists at key centers, with HLS ready to take responsibility for the product in Q1 next year. Management estimated potential peak revenue of approximately $5 million to $10 million.
  • NEXLIZET Launch PotentialHLS expected a Health Canada decision on NEXLIZET by year-end and, assuming approval, expected a launch in the first half of 2027. Management described NEXLIZET as a market expansion opportunity that could strengthen HLS's position in second-line LDL lowering, although it also acknowledged some replacement of patients taking both therapies.
  • NILEMDO and NEXLIZET Peak Sales OpportunityBased on progress to date, management remained confident that the combined NILEMDO/NEXLIZET peak sales opportunity would be in the range of CAD 50 million to CAD 100 million. Management said peak sales in Canada typically occur about 6 to 7 years after launch.
  • HLS Assist Patient Support ProgramHLS launched HLS Assist for eligible patients prescribed Vascepa or NILEMDO. The program offers reimbursement navigation and co-pay assistance to reduce barriers to starting and staying on therapy, and is designed to scale across multiple cardiovascular products.
  • Cardiovascular Community EngagementAt the Canadian Cardiovascular Congress, HLS supported educational sessions on Vascepa and non-statin prevention therapies, held an advisory board with Canadian cardiologists and lipid specialists, and launched CVD Prevention Research Awards with the Canadian Cardiovascular Foundation. Management reported strong engagement and enthusiasm for NILEMDO and anticipation for NEXLIZET.
  • Clozaril Patient Retention and Regional GrowthClozaril patient growth in Canada was coming from the West, with solid gains in D.C., Alberta and Saskatchewan. In Quebec, HLS continued to retain approximately 97% of patients on branded Clozaril annually, and nationally the patient base grew sequentially each month in Q3.
  • Clozaril Ontario Market PositionHLS continued defending its leading Clozaril market share in Ontario despite competitive pressures. Patient volumes in Ontario and nationally grew each month for the last 8 months, although Ontario sales can be lumpy because products are distributed through hospitals.
  • Clozaril Cash GenerationClozaril generated direct brand contribution of $6.3 million to adjusted EBITDA in Q3 and $18.7 million year-to-date. Management said it remained a high-margin, cash-generating business that helps fund growth in other parts of the company.
  • Debt Reduction and Lower Interest ExpenseThe term loan principal balance was $41.3 million at September 30, 2026, down 17% from the end of 2025, while net debt was $29.9 million, down 22%. Year-to-date interest expense was $2 million versus $4.3 million in the prior-year period, and trailing 12-month net interest paid declined from as high as $8.8 million to $2.7 million.
  • Capital Generation ImprovementTrailing 12-month adjusted EBITDA less royalty revenue and net interest paid increased to $15.3 million at the end of Q3 from $14.7 million at the end of Q2 and $2.3 million at the beginning of 2024.
  • Share Repurchases and Capital Allocation FlexibilityHLS expanded its normal course issuer bid to 1.9 million shares in September. Through October 31, the company had repurchased more than 1.1 million shares, returning CAD 4.3 million to shareholders. Management said the balance sheet provided flexibility to invest in launches, pursue business development and return capital to shareholders.
  • 2027 and 2028 Growth OutlookManagement expected a step-up in consolidated revenue and adjusted EBITDA growth in 2027 and further acceleration in 2028, driven by the cardiovascular portfolio, expanding NILEMDO margins, the potential NEXLIZET launch and the VERQUVO rollout.
  • Board ExpansionHLS welcomed two new independent directors on October 1: Dr. Linda Maxwell, bringing scientific and governance expertise, and Mark DeLong, bringing business development and corporate strategy experience in specialty pharmaceuticals.

DE:74D Earnings History

DE:74D earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 18, 20272026 (Q4)-0.03--0.04――
Nov 12, 20262026 (Q3)-0.06-0.06-0.1141.67% (+0.05)
Aug 12, 20262026 (Q2)-0.07-0.03-0.0866.67% (+0.05)
Mar 12, 20262025 (Q4)-0.03-0.04-0.0960.00% (+0.05)
Nov 13, 20252025 (Q3)-0.06-0.11-0.1420.00% (+0.03)
Nov 13, 20252026 (Q1)-0.11-0.06-0.1350.00% (+0.06)
Aug 14, 20252025 (Q2)-0.07-0.08-0.1650.00% (+0.08)
May 08, 20252025 (Q1)-0.11-0.13-0.1726.32% (+0.05)
Mar 13, 20252024 (Q4)-0.08-0.09-0.1541.18% (+0.06)
Nov 07, 20242024 (Q3)-0.11-0.14-0.1928.57% (+0.05)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed